| | L.E.K.’s Looking Ahead 2022 series of Executive Insights looks at how accelerated innovation has brought both unprecedented achievement and enduring challenges for companies throughout the healthcare ecosystem. Click to read more. |
|---|
Amarin stands behind Vascepa after new analysis raises questions about its efficacy Déjà vu: FDA rejects NRx filing for emergency use in COVID-19 Meet the executive leading UnitedHealthcare's social determinants strategy Northwestern researchers develop dissolving, nerve-cooling device for drug-free pain relief Novartis buys FDA priority review voucher from bankrupt Mallinckrodt for $100M How much health insurers pay for almost everything is about to go public Otsuka pays Akebia $55M to exit anemia pill pacts amid dispute and FDA rejection Medtronic completes initial closing in $50M purchase of Acutus’ left-heart access devices HHS issues guidance on patient privacy in wake of SCOTUS abortion ruling VC biotech funding drops 46% in first quarter as firms guard against bear market Oxford Biomedica signs up for 3 more years of making AstraZeneca COVID shots—on an 'as needed basis' FDA clears LiveMetric’s smartwatch-like, cuffless blood pressure sensor Featured Story | By Zoey Becker Even as Amarin's Vascepa is under siege from generics in the U.S., a new analysis raises questions about the company's key cardiovascular drug. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Aviptadil has gone 0 for 2 on emergency use authorization filings at the FDA. The new rejection is the latest in a series of blows to the COVID-19 candidate, driving NRx Pharmaceuticals to shift focus to its bipolar depression prospect. read more By Paige Minemyer At UnitedHealthcare, the scale and reach of the country's largest private insurer enable investments and initiatives that serve as a critical backbone to its relationship with members, said Andrew Billioux, M.D., vice president of social determinants of health at UHC. read more By Andrea Park As the opioid epidemic rages on, healthcare providers and scientists are still searching for a less addictive alternative to the drugs for pain relief. read more By Angus Liu Novartis is buying a pass to expedite FDA review for a future drug application. For $100 million, the Swiss pharma is acquiring a priority review voucher from opioid crisis-crippled Mallinckrodt. read more By Julie Appleby, Kaiser Health News New government rules force health insurers to publicly disclose what they pay for just about every service. That information could help consumers and employers know whether they’re getting a fair deal. read more By Nick Paul Taylor Akebia Therapeutics has extracted one final payday from Otsuka Pharmaceutical. With Otsuka cutting its ties to oral anemia drug vadadustat in the wake of rejection by the FDA, Akebia has secured a $55 million settlement, sending its bargain basement share price up 50% in after-hours trading. read more By Andrea Park Medtronic is now the proud owner of a handful of left-heart access devices, designed to help surgeons make the journey from the right atrium of the heart to the left in procedures for left-atrial appendage closure, mitral valve repair, atrial fibrillation ablation and more. read more By Heather Landi Healthcare providers are not permitted to disclose patient health information unless faced with a court order, including information relating to abortion and other sexual and reproductive health care, HHS said Wednesday. read more By Annalee Armstrong Just when biotechs could use cash the most, the well has dried up. Venture financing deal value for U.S.-based biotechs fell by 46% in the first quarter, compared to the same period a year ago, according to GlobalData. read more By Kevin Dunleavy Oxford Biomedica has revealed an extension of its contract with AstraZeneca to produce COVID-19 vaccines through 2025, but only on an “as needed basis,” the company said. This comes just nine months after Oxford announced a $68 million investment from the over-strapped Serum Institute of India to increase its ability to manufacture vaccines for AZ at its Oxbox facility. read more By Conor Hale No more squeezing: The FDA has cleared a smartwatch-like blood pressure device that foregoes the need for an inflatable cuff. read more | 